Novel glucose-lowering drugs for non-alcoholic fatty liver disease

Figure 1 Flow chart of included studies.

Figure 2 Alanine aminotransferase and aspartate aminotransferase changes from baseline in non-alcoholic fatty liver disease patients treated with novel glucose-lowering drugs. A: Alanine aminotransferase (ALT) changes with dipeptidyl peptidase-4 inhibitor treatment; B: Aspartate aminotransferase (AST) changes with dipeptidyl peptidase-4 inhibitor treatment; C: ALT changes with glucagon-like peptide-1 receptor agonist treatment; D: AST changes with glucagon-like peptide-1 receptor agonist treatment; E: ALT changes with sodium-glucose cotransporter 2 inhibitor treatment; F: AST changes with sodium-glucose cotransporter 2 inhibitor treatment.